RecruitingPhase 4NCT07290257
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
Studying Alagille syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Intervention
- Livmarli Oral Product(drug)
- Enrollment
- 100 enrolled
- Eligibility
- All sexes
- Timeline
- 2025 – 2030
Study locations (13)
- Cliniques Universitaires Saint Luc (UCLouvain), Brussels, Belgium
- University Hospital Gent (UZ Gent), Ghent, Belgium
- Hospices Civils de Lyon - Hopital Femme Mère Enfant, Bron, Auvergne-Rhône-Alpes, France
- CHU de Toulouse - Hôpital des Enfants, Toulouse, Occitanie, France
- Bicetre University Hospital, Le Kremlin-Bicêtre, Île-de-France Region, France
- Charite Berlin, Berlin, Germany
- Children's University Hospital Essen, Essen, Germany
- University Hospital Hamburg-Eppendorf, Hamburg, Germany
- AO Ospedale PAPA GIOVANNI XXIII, Bergamo, Lombardy, Italy
- Istituto mediterraneo trapianti - ISMETT, Palermo, Sicily, Italy
- University Medical Center Groningen (UMCG), Groningen, Netherlands
- Hospital Universitairo Vall D'Hebron, Barcelona, Catalonia, Spain
- Hospital Universitario La Paz, Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07290257 on ClinicalTrials.govOther trials for Alagille syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07411716Pediatric Evaluation and Registry for Liver Cholestasis in CanadaChildren's Hospital of Eastern Ontario
- RECRUITINGNCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)Takeda
- RECRUITINGNCT06850038A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentIpsen
- RECRUITINGNCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)Mirum Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT05035030Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeAlbireo, an Ipsen Company